Literature DB >> 17432821

Activating B cell signaling with defined multivalent ligands.

Erik B Puffer1, Jason K Pontrello, Jessica J Hollenbeck, John A Kink, Laura L Kiessling.   

Abstract

Depending on the stimuli they encounter, B lymphocytes engage in signaling events that lead to immunity or tolerance. Both responses are mediated through antigen interactions with the B cell antigen receptor (BCR). Antigen valency is thought to be an important parameter in B cell signaling, but systematic studies are lacking. To explore this issue, we synthesized multivalent ligands of defined valencies using the ring-opening metathesis polymerization (ROMP). When mice are injected with multivalent antigens generated by ROMP, only those of high valencies elicit antibody production. These results indicate that ligands synthesized by ROMP can activate immune responses in vivo. All of the multivalent antigens tested activate signaling through the BCR. The ability of antigens to cluster the BCR, promote its localization to membrane microdomains, and augment intracellular Ca2+ concentration increases as a function of antigen valency. In contrast, no differences in BCR internalization were detected. Our results indicate that differences in the antigenicity of BCR ligands are related to their ability to elicit increases in intracellular Ca2+ concentration. Finally, we observed that unligated BCRs cluster with BCRs engaged by multivalent ligands, a result that suggests that signals mediated by the BCR are amplified through receptor arrays. Our data suggest a link between the mechanisms underlying signal initiation by receptors that must respond with high sensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17432821     DOI: 10.1021/cb600489g

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  65 in total

1.  The growth of B cell receptor microcluster is a universal response of B cells encountering antigens with different motion features.

Authors:  Zhengpeng Wan; Wanli Liu
Journal:  Protein Cell       Date:  2012-07-10       Impact factor: 14.870

2.  Grand challenge commentary: Synthetic immunology to engineer human immunity.

Authors:  David A Spiegel
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

3.  Modulating adaptive immune responses to peptide self-assemblies.

Authors:  Jai S Rudra; Tao Sun; Katelyn C Bird; Melvin D Daniels; Joshua Z Gasiorowski; Anita S Chong; Joel H Collier
Journal:  ACS Nano       Date:  2012-01-30       Impact factor: 15.881

4.  Polymer-Based Therapeutics.

Authors:  Shuang Liu; Ronak Maheshwari; Kristi L Kiick
Journal:  Macromolecules       Date:  2009-01-13       Impact factor: 5.985

5.  Neuroactive chondroitin sulfate glycomimetics.

Authors:  Manish Rawat; Cristal I Gama; John B Matson; Linda C Hsieh-Wilson
Journal:  J Am Chem Soc       Date:  2008-02-15       Impact factor: 15.419

6.  Materials science. Polymer therapeutics.

Authors:  Kristi L Kiick
Journal:  Science       Date:  2007-08-31       Impact factor: 47.728

7.  Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation.

Authors:  Adam H Courtney; Erik B Puffer; Jason K Pontrello; Zhi-Qiang Yang; Laura L Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

8.  Enhanced potency of the metalloprotease inhibitor TAPI-2 by multivalent display.

Authors:  Aram J Raissi; Frank A Scangarello; Kaitlin R Hulce; Jason K Pontrello; Suzanne Paradis
Journal:  Bioorg Med Chem Lett       Date:  2014-02-14       Impact factor: 2.823

9.  A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.

Authors:  Hsiao-Ling Chiang; Chi-Yu Lin; Fan-Dan Jan; Yaoh-Shiang Lin; Chia-Tse Hsu; Jacqueline Whang-Peng; Leroy F Liu; Shin Nieh; Chun-Cheng Lin; Jaulang Hwang
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

10.  Engineering filamentous phage carriers to improve focusing of antibody responses against peptides.

Authors:  Nienke E van Houten; Kevin A Henry; George P Smith; Jamie K Scott
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.